V. BeralC. HermonR. PetoG. ReevesL. BrintonP. MarchbanksE. NegriR. B. NessP. H.M. PeetersM. VesseyE. E. CalleS. M. GapsturA. V. PatelL. Dal MasoR. TalaminiA. ChetritG. Hirsh-YechezkelF. LubinS. SadetzkiN. AllenD. BullK. CallaghanB. CrossleyK. GaitskellA. GoodillJ. GreenT. KeyK. MoserR. CollinsR. DollC. A. GonzalezN. LeeH. W. OryH. B. PetersonP. A. WingoN. MartinT. PardthaisongS. SilpisornkosolC. TheetranontB. BoosiriS. ChutivongseP. JimakornP. VirutamasenC. WongsrichanalaiA. TjonnelandL. Titus-ErnstoffT. ByersT. RohanB. J. MosgaardD. YeatesJ. L. FreudenheimJ. Chang-ClaudeR. KaaksK. E. AndersonA. FolsomM. A. RossingD. B. ThomasN. S. WeissE. RiboliF. Clavel-ChapelonD. CramerK. RobienS. S. TworogerD. CramerS. E. HankinsonS. S. TworogerS. FranceschiC. La VecchiaC. MagnussonT. RimanE. WeiderpassA. WolkL. J. SchoutenP. A. Van den BrandtN. ChantarakulS. KoetsawangD. RachawatD. PalliA. BlackA. Berrington de GonzalezD. M. FreedmanP. HartgeA. W. HsingJ. V. LaceyR. N. HooverC. SchairerS. Graff-IversenR. SelmerC. J. BainA. C. GreenD. M. PurdieV. SiskindP. M. WebbAmerican Cancer SocietyIRCCS Centro Di Riferimento Oncologico AvianoThe Gertner InstituteCancer Epidemiology UnitClinical Trial Service UnitInstitute Catala OncologiaCenters for Disease Control and PreventionChiang Mai UniversityChulalongkorn UniversityInstitute of Cancer Epidemiology - DenmarkGeisel School of Medicine at DartmouthColorado School of Public HealthAlbert Einstein College of Medicine of Yeshiva UniversityAmtssygehuset i HerlevDepartment of Public HealthUniversity at Buffalo, State University of New YorkGerman Cancer Research CenterUniversity of Minnesota School of Public HealthUniversity of Washington, SeattleImperial College LondonCentre de recherche en epidemiologie et sante des populationsHarvard Medical SchoolBrigham and Women's HospitalChanning LaboratoryInternational Agency for Research on CancerUniversita degli Studi di MilanoKarolinska InstitutetMaastricht UniversityMahidol UniversityCentro Per Lo Studio E La Prevenzione OncologicaNational Cancer InstituteNorwegian Institute of Public HealthQueensland Institute of Medical ResearchRoswell Park Cancer InstituteRoyal College of General Practitioners' Oral Contraception StudyCurtin UniversityUniversity of Texas SystemUniversity of Massachusetts SystemBoston UniversityStanford UniversityUniversity of Athens Medical SchoolUniversidad de ChileUniversity of Hawaii SystemSkånes universitetssjukhusUniversity of PennsylvaniaUniversity Medical Center UtrechtUniversity of Southern CaliforniaUniversity of TorontoUniversitetet i TromsoGeorge Washington UniversityVanderbilt UniversityOrganisation Mondiale de la SanteYale University2018-06-112018-06-112012-04-01PLoS Medicine. Vol.9, No.4 (2012)15491676154912772-s2.0-84860157091https://repository.li.mahidol.ac.th/handle/20.500.14594/14892Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p < 0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p < 0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m 2 increase in body mass index was 1.10 (95% CI, 1.07-1.13; p < 0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade. © 2012 Collaborative Group on Epidemiological Studies of Ovarian Cancer.Mahidol UniversityMedicineArticleSCOPUS10.1371/journal.pmed.1001200